For 6 years, Hyperdynamics, a very small oil E&P company with rights to a giant and very promising concession offshore west Africa, languished under the inept leadership of its CEO, K.W. Its stock price dipped to as low 35 cents.

That's all changed over the past few weeks. HDY's stockholders rebelled, kicked out K.W. and forced the BOD to hire an executive search firm to find a new CEO with real experience in oil exploration.

The results exceeded expectations. Ray Leonard is now leading Hyperdynamics, bringing with him vast executive experience and a solid record of accomplishments in South America, Russia and southwest Asia. His name is well-known in the industry, and he often highlights conferences on the situation with 'peak oil'. Leonard's compensation will depend almost entirely on getting HDY's stock price up.

I see BOCX in the same situation HDY found itself, with the key difference that Dr. Moro actually knows something about research and cancer. But I don't think Dr. Moro knows how to get things done industry-wise, or at least done by optimum strategies. Like HDY, BOCX has an immensely valuable concession: the RECAF antibody. And like HDY for so many years, no one seems to take Biocurex very seriously.

Biocurex needs a new CEO. Dr. Moro is our key asset, but he needs to concentrate on being Cheif Scientist. We need someone with industrial mojo and a name in the business. Someone who will make ears perk up and listen when he talks and make folks in the audience nudge each other and say, "Hey, I know that guy! Isn't he the one who doubled Smith&Jones' market share, and got Unobtainium accepted by the FDA?..."

And it wouldn't cost Biocurex hardly anything. Just offer a pittance yearly salary--but with milestone/price-trigger stock options.

If RECAF is really all it is, it's a no-brainer.